6848 Stock Overview
Researches, develops, manufactures, and sells reagents and devices for life science and molecular diagnosis in Europe, the United States, Asia, Taiwan, Africa, and Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 2/6 |
| Dividends | 4/6 |
RBC Bioscience Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$19.95 |
| 52 Week High | NT$24.60 |
| 52 Week Low | NT$14.50 |
| Beta | 0.065 |
| 11 Month Change | -16.18% |
| 3 Month Change | 5.84% |
| 1 Year Change | 32.56% |
| 33 Year Change | -47.31% |
| 5 Year Change | n/a |
| Change since IPO | -59.06% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6848 | TW Life Sciences | TW Market | |
|---|---|---|---|
| 7D | -2.2% | -3.0% | -3.4% |
| 1Y | 32.6% | -14.4% | 30.2% |
Return vs Industry: 6848 exceeded the TW Life Sciences industry which returned -14.4% over the past year.
Return vs Market: 6848 exceeded the TW Market which returned 30.2% over the past year.
Price Volatility
| 6848 volatility | |
|---|---|
| 6848 Average Weekly Movement | 5.7% |
| Life Sciences Industry Average Movement | 4.0% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in TW Market | 8.0% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 6848 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 6848's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | n/a | n/a | www.rbcbioscience.com |
RBC Bioscience Corporation researches, develops, manufactures, and sells reagents and devices for life science and molecular diagnosis in Europe, the United States, Asia, Taiwan, Africa, and Australia. It offers molecular biomedical diagnostic and research reagents, gene extraction automatic testing instruments, and gene extraction reagent tissues; automated nucleic acid extractors; and nucleic acid extraction kits. The company sells its products through distributors.
RBC Bioscience Corporation Fundamentals Summary
| 6848 fundamental statistics | |
|---|---|
| Market cap | NT$258.86m |
| Earnings (TTM) | NT$17.27m |
| Revenue (TTM) | NT$194.62m |
15.0x
P/E Ratio1.3x
P/S RatioIs 6848 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6848 income statement (TTM) | |
|---|---|
| Revenue | NT$194.62m |
| Cost of Revenue | NT$106.26m |
| Gross Profit | NT$88.36m |
| Other Expenses | NT$71.09m |
| Earnings | NT$17.27m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.33 |
| Gross Margin | 45.40% |
| Net Profit Margin | 8.87% |
| Debt/Equity Ratio | 185.5% |
How did 6848 perform over the long term?
See historical performance and comparison